tiprankstipranks
Advertisement
Advertisement

TVTX Stock Latest News

Travere Therapeutics Announces R&D Leadership Transition Plan
Company AnnouncementsTravere Therapeutics Announces R&D Leadership Transition Plan
4d ago
8K
TVTX
Travere Therapeutics announces retirement of Chief Research Officer in 2027
PremiumThe Fly
Travere Therapeutics announces retirement of Chief Research Officer in 2027
4d ago
TVTX
Travere Therapeutics price target raised to $70 from $62 at Citi
PremiumThe Fly
Travere Therapeutics price target raised to $70 from $62 at Citi
5d ago
TVTX
Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
PremiumMarket News
Mega-Cap Concentration Has Hidden Active Growth’s Best Story: Inside the F/m Emerald Special Situations ETF (SPIT) and a 1st-Percentile Morningstar Track Record
8d ago
EE
GH
Travere Therapeutics says Filspari generally well tolerated in Phase 3 study
PremiumThe Fly
Travere Therapeutics says Filspari generally well tolerated in Phase 3 study
16d ago
TVTX
Travere Therapeutics price target raised to $62 from $59 at Citi
PremiumThe FlyTravere Therapeutics price target raised to $62 from $59 at Citi
17d ago
TVTX
Analyst Reiterates Buy on Travere as Civorebrutinib Deal Expands Renal Franchise; $56 Price Target Maintained
Premium
Ratings
Analyst Reiterates Buy on Travere as Civorebrutinib Deal Expands Renal Franchise; $56 Price Target Maintained
17d ago
TVTX
Travere Therapeutics price target raised to $67 from $57 at H.C. Wainwright
Premium
The Fly
Travere Therapeutics price target raised to $67 from $57 at H.C. Wainwright
18d ago
TVTX
Travere Therapeutics enters into exclusive licensing agreement with Everest
PremiumThe Fly
Travere Therapeutics enters into exclusive licensing agreement with Everest
18d ago
TVTX
Travere Licenses Civorebrutinib, Expands Kidney Disease Pipeline
PremiumCompany Announcements
Travere Licenses Civorebrutinib, Expands Kidney Disease Pipeline
18d ago
8K
TVTX
Ligand price target raised to $266 from $263 at BofA
PremiumThe Fly
Ligand price target raised to $266 from $263 at BofA
23d ago
LGND
TVTX
Travere Therapeutics price target raised to $59 from $50 at BofA
PremiumThe Fly
Travere Therapeutics price target raised to $59 from $50 at BofA
23d ago
TVTX
Travere confirms Notice of Allowance from USPTO for Filspari patent application
PremiumThe FlyTravere confirms Notice of Allowance from USPTO for Filspari patent application
23d ago
TVTX
Wells says new Filspari patent allowance improves Travere’s settlement leverage
Premium
The Fly
Wells says new Filspari patent allowance improves Travere’s settlement leverage
24d ago
TVTX
Travere Shareholders Reinforce Governance and Compensation Framework
Premium
Company Announcements
Travere Shareholders Reinforce Governance and Compensation Framework
30d ago
8K
TVTX
Travere Therapeutics Rides FILSPARI Surge After FDA Win
PremiumCompany Announcements
Travere Therapeutics Rides FILSPARI Surge After FDA Win
1M ago
TVTX
Travere Therapeutics Issues New Convertible Notes to Refinance Debt
PremiumCompany Announcements
Travere Therapeutics Issues New Convertible Notes to Refinance Debt
1M ago
8K
TVTX
Travere Therapeutics announces $400M convertible senior notes offering
PremiumThe Fly
Travere Therapeutics announces $400M convertible senior notes offering
2M ago
TVTX
Edward Nash Reiterates Buy on Travere, Maintaining $56 Price Target Amid Strong Filspari Momentum and Expanding Renal Franchise
PremiumRatings
Edward Nash Reiterates Buy on Travere, Maintaining $56 Price Target Amid Strong Filspari Momentum and Expanding Renal Franchise
2M ago
TVTX
Travere Therapeutics price target raised to $60 from $45 at TD Cowen
PremiumThe FlyTravere Therapeutics price target raised to $60 from $45 at TD Cowen
2M ago
TVTX
Travere Therapeutics price target raised to $55 from $53 at Wedbush
Premium
The Fly
Travere Therapeutics price target raised to $55 from $53 at Wedbush
2M ago
TVTX
Travere Therapeutics price target raised to $59 from $53 at Citi
Premium
The Fly
Travere Therapeutics price target raised to $59 from $53 at Citi
2M ago
TVTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >